GlassScriptPhysician profile
Christopher Earnhardt
NPI 1699762948
$5,280.04
in general payments reported to CMS, 2019-2025
34 companies · $745 in 2025
The $745 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $340 · 2021: $923 · 2022: $948 · 2023: $900 · 2024: $956 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,540 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,539.93 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,467.73 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $550.41 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $520.48 | 2019-2025 | |
| Glaxosmithkline, LLC. | $491.51 | 2019-2024 | Trelegy Ellipta, Bexsero, Shingrix |
| Astrazeneca Pharmaceuticals LP | $456.39 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $405.38 | 2019-2023 | Myrbetriq |
| Sunovion Pharmaceuticals INC. | $180.72 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.44 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $119.14 | 2019-2022 | |
| Amgen INC. | $102.38 | 2019-2021 | |
| Lilly USA, LLC | $99.47 | 2019-2024 | Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $89.14 | 2021-2024 | |
| Allergan, INC. | $54.44 | 2019-2020 | |
| Mylan Specialty L.P. | $51.92 | 2019-2024 | Yupelri |
| Eisai INC. | $49.64 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $47.17 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $46.53 | 2020-2025 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $39.62 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $36.48 | 2019-2025 | Qelbree |
| Phathom Pharmaceuticals, INC. | $36.23 | 2024-2025 | Voquezna |
| Abbott Laboratories | $34.81 | 2022 | |
| Inogen, INC. | $27.68 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| E.R. Squibb & Sons, L.L.C. | $26.04 | 2019 | |
| Shield Therapeutics INC | $25.96 | 2023 | Accrufer |
| Dexcom, INC. | $22.11 | 2024 | Dexcom G6 Transmitter |
| Abiomed | $21.00 | 2024 | Impella |
| Kowa Pharmaceuticals America, INC. | $18.78 | 2021 | |
| Sanofi Pasteur INC. | $18.02 | 2025 | |
| Vanda Pharmaceuticals INC. | $17.60 | 2025 | Fanapt |
| Sumitomo Pharma America, INC. | $17.18 | 2025 | Gemtesa |
| Daiichi Sankyo INC. | $15.47 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.02 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.85 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.30 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Earnhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.